The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
09 05 2023
09 05 2023
Historique:
received:
15
03
2022
accepted:
24
04
2023
medline:
11
5
2023
pubmed:
10
5
2023
entrez:
10
5
2023
Statut:
epublish
Résumé
Pneumococcal conjugate vaccines (PCVs) protect against invasive pneumococcal disease (IPD) among vaccinees. However, at population level, this protection is driven by indirect effects. PCVs prevent nasopharyngeal acquisition of vaccine-serotype (VT) pneumococci, reducing onward transmission. Each disease episode is preceded by infection from a carrier, so vaccine impacts on carriage provide a minimum estimate of disease reduction in settings lacking expensive IPD surveillance. We documented carriage prevalence and vaccine coverage in two settings in Nigeria annually (2016-2020) following PCV10 introduction in 2016. Among 4,684 rural participants, VT carriage prevalence fell from 21 to 12% as childhood (<5 years) vaccine coverage rose from 7 to 84%. Among 2,135 urban participants, VT carriage prevalence fell from 16 to 9% as uptake rose from 15 to 94%. Within these ranges, carriage prevalence declined with uptake. Increasing PCV10 coverage reduced pneumococcal infection at all ages, implying at least a comparable reduction in IPD.
Identifiants
pubmed: 37160867
doi: 10.1038/s41467-023-38277-z
pii: 10.1038/s41467-023-38277-z
pmc: PMC10169786
doi:
Substances chimiques
10-valent pneumococcal conjugate vaccine
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2666Subventions
Organisme : Wellcome Trust
ID : 214320
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Sci Rep. 2018 Feb 22;8(1):3509
pubmed: 29472635
Vaccine. 2013 Dec 17;32(1):165-79
pubmed: 24331112
Expert Rev Vaccines. 2020 Mar;19(3):247-265
pubmed: 32195602
Epidemics. 2018 Dec;25:72-79
pubmed: 30054196
BMC Med. 2019 Dec 5;17(1):219
pubmed: 31801542
Lancet Glob Health. 2014 Jul;2(7):e397-405
pubmed: 25103393
Vaccine. 2019 Oct 8;37(43):6299-6309
pubmed: 31500968
Lancet. 2005 Mar 26-Apr 1;365(9465):1139-46
pubmed: 15794968
Vaccine. 2020 Jan 10;38(2):202-211
pubmed: 31668367
Expert Rev Vaccines. 2019 Jun;18(6):641-661
pubmed: 31230486
Lancet Infect Dis. 2021 Apr;21(4):e93-e102
pubmed: 33129426
Vaccine. 2016 Nov 4;34(46):5604-5611
pubmed: 27692770
Vaccine. 2010 Dec 16;29(2):283-8
pubmed: 21029807
Vaccine. 2018 May 3;36(19):2559-2566
pubmed: 29650385
BMC Infect Dis. 2018 Apr 11;18(1):172
pubmed: 29642869
PLoS Med. 2011 Apr;8(4):e1001017
pubmed: 21483718
Epidemiol Infect. 2017 Oct;145(13):2750-2758
pubmed: 28847317
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Vaccine. 2013 Dec 17;32(1):133-45
pubmed: 23684824
Vaccine. 2018 Dec 18;36(52):7965-7974
pubmed: 30416017
Expert Rev Vaccines. 2012 Jul;11(7):841-55
pubmed: 22913260
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):109-117
pubmed: 35085226
Vaccine. 2011 Oct 19;29(45):8042-8
pubmed: 21871518
Vaccine. 2017 Aug 16;35(35 Pt B):4561-4568
pubmed: 28729018
BMC Infect Dis. 2015 Jun 20;15:234
pubmed: 26088623
Hum Vaccin Immunother. 2016;12(2):358-74
pubmed: 26905681
Vaccine. 2017 Jul 13;35(32):4002-4009
pubmed: 28645717
Nat Commun. 2020 May 6;11(1):2222
pubmed: 32376860
Lancet Glob Health. 2017 Jan;5(1):e51-e59
pubmed: 27955789
Lancet. 2019 May 25;393(10186):2146-2154
pubmed: 31000194
Lancet. 2011 Dec 3;378(9807):1962-73
pubmed: 21492929
PLoS One. 2015 Jul 01;10(7):e0129649
pubmed: 26132206